Product Details for ANDA 090030
OXALIPLATIN (OXALIPLATIN)
50MG/10ML (5MG/ML)
Marketing Status: Prescription
100MG/20ML (5MG/ML)
Marketing Status: Prescription
200MG/40ML (5MG/ML)
Marketing Status: Discontinued
50MG/10ML (5MG/ML)
Marketing Status: Prescription
Active Ingredient: OXALIPLATIN
Proprietary Name: OXALIPLATIN
Dosage Form; Route of Administration: INJECTABLE; INTRAVENOUS
Strength: 50MG/10ML (5MG/ML)
Reference Listed Drug: No
Reference Standard: No
TE Code: AP
Application Number: A090030
Product Number: 001
Approval Date: Jan 31, 2017
Applicant Holder Full Name: FRESENIUS KABI USA LLC
Marketing Status: Prescription
Patent and Exclusivity Information
OXALIPLATIN (OXALIPLATIN)
Proprietary Name: OXALIPLATIN
Dosage Form; Route of Administration: INJECTABLE; INTRAVENOUS
Strength: 50MG/10ML (5MG/ML)
Reference Listed Drug: No
Reference Standard: No
TE Code: AP
Application Number: A090030
Product Number: 001
Approval Date: Jan 31, 2017
Applicant Holder Full Name: FRESENIUS KABI USA LLC
Marketing Status: Prescription
Patent and Exclusivity Information
100MG/20ML (5MG/ML)
Marketing Status: Prescription
Active Ingredient: OXALIPLATIN
Proprietary Name: OXALIPLATIN
Dosage Form; Route of Administration: INJECTABLE; INTRAVENOUS
Strength: 100MG/20ML (5MG/ML)
Reference Listed Drug: No
Reference Standard: No
TE Code: AP
Application Number: A090030
Product Number: 002
Approval Date: Jan 31, 2017
Applicant Holder Full Name: FRESENIUS KABI USA LLC
Marketing Status: Prescription
Patent and Exclusivity Information
OXALIPLATIN (OXALIPLATIN)
Proprietary Name: OXALIPLATIN
Dosage Form; Route of Administration: INJECTABLE; INTRAVENOUS
Strength: 100MG/20ML (5MG/ML)
Reference Listed Drug: No
Reference Standard: No
TE Code: AP
Application Number: A090030
Product Number: 002
Approval Date: Jan 31, 2017
Applicant Holder Full Name: FRESENIUS KABI USA LLC
Marketing Status: Prescription
Patent and Exclusivity Information
200MG/40ML (5MG/ML)
Marketing Status: Discontinued
Active Ingredient: OXALIPLATIN
Proprietary Name: OXALIPLATIN
Dosage Form; Route of Administration: INJECTABLE; INTRAVENOUS
Strength: 200MG/40ML (5MG/ML)
Reference Listed Drug: No
Reference Standard: No
TE Code:
Application Number: A090030
Product Number: 003
Approval Date: Jan 31, 2017
Applicant Holder Full Name: FRESENIUS KABI USA LLC
Marketing Status: Discontinued
Patent and Exclusivity Information
Proprietary Name: OXALIPLATIN
Dosage Form; Route of Administration: INJECTABLE; INTRAVENOUS
Strength: 200MG/40ML (5MG/ML)
Reference Listed Drug: No
Reference Standard: No
TE Code:
Application Number: A090030
Product Number: 003
Approval Date: Jan 31, 2017
Applicant Holder Full Name: FRESENIUS KABI USA LLC
Marketing Status: Discontinued
Patent and Exclusivity Information